Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.19% $0.908
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 31.52 mill |
EPS: | -0.650 |
P/E: | -1.400 |
Earnings Date: | May 11, 2024 |
SharesOutstanding: | 34.70 mill |
Avg Daily Volume: | 0.0533 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.400 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.24x |
Company: PE -1.400 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.0980 (-89.21%) $-0.810 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 0.841 - 0.975 ( +/- 7.38%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Behner Peter | Buy | 16 185 | Common Stock |
2024-03-01 | Ryan Barbara | Buy | 18 685 | Common Stock |
2024-03-01 | Wiinberg Ulf | Buy | 15 790 | Common Stock |
2024-03-01 | Corvese Brian | Buy | 18 816 | Common Stock |
2024-01-16 | Van Dijk Marcus Antonius | Buy | 171 078 | Stock Option |
INSIDER POWER |
---|
-44.11 |
Last 97 transactions |
Buy: 6 422 397 | Sell: 29 448 104 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.908 (-0.19% ) |
Volume | 0.0350 mill |
Avg. Vol. | 0.0533 mill |
% of Avg. Vol | 65.64 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.